During the last three months, 26 analysts shared their evaluations of Gilead Sciences GILD, revealing diverse outlooks from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 1 | 12 | 13 | 0 | 0 |
| Last 30D | 0 | 0 | 1 | 0 | 0 |
| 1M Ago | 1 | 7 | 7 | 0 | 0 |
| 2M Ago | 0 | 4 | 2 | 0 | 0 |
| 3M Ago | 0 | 1 | 3 | 0 | 0 |
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $92.73, with a high estimate of $125.00 and a low estimate of $70.00. This current average has increased by 12.55% from the previous average price target of $82.39.
Deciphering Analyst Ratings: An In-Depth Analysis
The standing of Gilead Sciences among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Brian Abrahams | RBC Capital | Raises | Sector Perform | $84.00 | $81.00 |
| Alexandria Hammond | Wolfe Research | Announces | Outperform | $110.00 | - |
| Geoff Meacham | Citigroup | Announces | Buy | $125.00 | - |
| Asthika Goonewardene | Truist Securities | Raises | Hold | $97.00 | $83.00 |
| Hartaj Singh | Oppenheimer | Raises | Outperform | $105.00 | $95.00 |
| Evan Seigerman | BMO Capital | Raises | Outperform | $102.00 | $94.00 |
| Brian Skorney | Baird | Raises | Neutral | $95.00 | $80.00 |
| Chris Schott | JP Morgan | Raises | Overweight | $105.00 | $100.00 |
| Brian Abrahams | RBC Capital | Raises | Sector Perform | $81.00 | $75.00 |
| Salveen Richter | Goldman Sachs | Raises | Neutral | $84.00 | $74.00 |
| Olivia Brayer | Cantor Fitzgerald | Raises | Neutral | $80.00 | $70.00 |
| Mohit Bansal | Wells Fargo | Raises | Overweight | $105.00 | $100.00 |
| Carter Gould | Barclays | Raises | Equal-Weight | $95.00 | $84.00 |
| Joseph Catanzaro | Piper Sandler | Raises | Overweight | $105.00 | $95.00 |
| Brian Abrahams | RBC Capital | Maintains | Sector Perform | $75.00 | $75.00 |
| Andrew Berens | Leerink Partners | Raises | Outperform | $96.00 | $74.00 |
| Evan Seigerman | BMO Capital | Raises | Outperform | $94.00 | $85.00 |
| Aaron Gal | Bernstein | Announces | Outperform | $105.00 | - |
| Chris Schott | JP Morgan | Raises | Overweight | $100.00 | $95.00 |
| Carter Gould | Barclays | Raises | Equal-Weight | $84.00 | $76.00 |
| Mohit Bansal | Wells Fargo | Raises | Overweight | $100.00 | $78.00 |
| Brian Abrahams | RBC Capital | Raises | Sector Perform | $75.00 | $74.00 |
| Olivia Brayer | Cantor Fitzgerald | Maintains | Neutral | $70.00 | $70.00 |
| Joseph Catanzaro | Piper Sandler | Maintains | Overweight | $95.00 | $95.00 |
| Olivia Brayer | Cantor Fitzgerald | Maintains | Neutral | $70.00 | $70.00 |
| Brian Abrahams | RBC Capital | Raises | Sector Perform | $74.00 | $72.00 |
Key Insights:
- Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Gilead Sciences. This information offers a snapshot of how analysts perceive the current state of the company.
- Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Gilead Sciences compared to the broader market.
- Price Targets: Delving into movements, analysts provide estimates for the future value of Gilead Sciences's stock. This analysis reveals shifts in analysts' expectations over time.
To gain a panoramic view of Gilead Sciences's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
Stay up to date on Gilead Sciences analyst ratings.
All You Need to Know About Gilead Sciences
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
Gilead Sciences: Financial Performance Dissected
Market Capitalization: Surpassing industry standards, the company's market capitalization asserts its dominance in terms of size, suggesting a robust market position.
Revenue Growth: Gilead Sciences's revenue growth over a period of 3 months has been noteworthy. As of 30 September, 2024, the company achieved a revenue growth rate of approximately 7.02%. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Gilead Sciences's net margin is impressive, surpassing industry averages. With a net margin of 16.61%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Gilead Sciences's ROE stands out, surpassing industry averages. With an impressive ROE of 6.82%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Gilead Sciences's ROA stands out, surpassing industry averages. With an impressive ROA of 2.32%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: Gilead Sciences's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 1.26.
Understanding the Relevance of Analyst Ratings
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in Benzinga Pro.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. Click here for urgent details.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
